HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.

Abstract
As a distinct type of aggressive mature large B-cell lymphoma, plasmablastic lymphoma (PBL) poses diagnostic and treatment challenges. PBL is distinguished from other B-cell lymphomas by the presence of plasmacytic differentiation markers such as CD38, CD138, and MUM1. Clinically, PBLs from oral and extra-oral sites are rapidly progressive tumors with frequent relapse after treatment with standard diffuse large B-cell lymphoma regimens. Here, we report a near-complete response of one patient with relapsed PBL following treatment with a non-cytotoxic regimen containing bortezomib, rituximab, and dexamethasone.
AuthorsMin Yan, Zhaoming Dong, Frank Zhao, Thomas Chauncey, Delva Deauna-Limayo, Jessica Wang-Rodriguez, Dayu Liu, Huan-You Wang, Renate Pilz
JournalEuropean journal of haematology (Eur J Haematol) Vol. 93 Issue 1 Pg. 77-80 (Jul 2014) ISSN: 1600-0609 [Electronic] England
PMID24528507 (Publication Type: Case Reports, Journal Article)
Copyright© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Boronic Acids
  • Pyrazines
  • Rituximab
  • Bortezomib
Topics
  • Antibodies, Monoclonal, Murine-Derived (administration & dosage)
  • Antigens, CD20 (immunology)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Boronic Acids (administration & dosage)
  • Bortezomib
  • Humans
  • Lymphoma, Non-Hodgkin (drug therapy, immunology)
  • Male
  • Middle Aged
  • Pyrazines (administration & dosage)
  • Rituximab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: